First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649 Meeting Abstract
| Authors: | Möhler, M.; Shitara, K.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A. C.; Liu, T.; Schenker, M.; Yanez, P.; Tehfe, M.; Li, M.; Cullen, D.; Memaj, A.; Lei, M.; Xiao, H.; Janjigian, Y. Y.; Ajani, J. A. |
| Abstract Title: | First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649 |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (Hybrid-Kongress) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 44 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Oct 01-04 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2021-09-01 |
| Start Page: | 79 |
| End Page: | 80 |
| Language: | English |
| ACCESSION: | WOS:000760622600139 |
| PROVIDER: | wos |
| DOI: | 10.1159/000518417 |
| Notes: | Meeting Abstract: V149 -- Meeting was also presented virtually -- "Joint Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (Hybrid Congress)" -- Source: Wos |
